November’s second CE took place at Pier A Harbor House in Battery Park. President, Dr. Yi Guo, and Immediate Past President, Dr. Amisha Arya, greeted members as they escaped the stormy weather and into the beautiful venue overlooking the harbor.
President Guo welcomed and thanked everyone for attending and arriving safely to tonight’s event. The first speaker was Sharmin Amaj, a final year student pharmacist at Long Island University. Sharmin’s presentation was titled the Role of Zerbaxa (Ceftolozane/Tazobactam) in Complicated Urinary Tract Infections. Sharmin discussed the indication and population for the benefit of Zerbaxa and highlighted the dosing regimen.
President Guo thanked NYCSHP’s Grant Writing Committee for their continual efforts and for receiving the grant to host tonight’s events. President Guo invited Evangelina Berrio-Colon, from the NYCSHP’s Grant Writing Committee, to the stage to introduce the evening’s CE speaker.
Dr. Evangelina Berrio-Colon introduced Philip Chung, PharmD, BCPS, Assistant Professor of Medicine at Albert Einstein College of Medicine, and Clinical Pharmacy Manager of Infectious Diseases at Montefiore Medical Center. Dr. Chung’s presentation was titled Are We Ad-vancin’ on Resistant Gram-positive Infections? The Role of Lipoglycopeptides.
Dr. Chung’s presentation gave us some insight on agents used to treat vancomcyin resistance and the benefit they have shown in studies and in our communities. The treatment options for VRE are daptomycin, linezolid, tigecycline, and quinupristin/dalfopristin, but these agents also have their limitations. Dr. Chung had described the mechanism of vancomycin and lipoglycopeptides and introduced telavancin, dalbavancin, and oritavancin.
Article and Photos by Jamie Chin